http://orcid.org/0000-0003-0655-8630
Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Djin-Ye Oh, Jeanette Milde, Youngsun Ham, Julia Patricia Ramos Calderón, Marianne Wedde, Ralf Dürrwald & Susanne C Duwe. (2024) Preparing for the Next Influenza Season: Monitoring the Emergence and Spread of Antiviral Resistance. Infection and Drug Resistance 16, pages 949-959.
Read now
Read now
Guangliang Huang, Yunfei Tian, Wenyan Cui, Xinhui Zhang, Yonghong Zhao & Xiuju Liu. (2023) Rapid health technology assessment of the novel endonuclease inhibitor baloxavir for the treatment of influenza. Journal of Chemotherapy 0:0, pages 1-16.
Read now
Read now
George N. Okoli, Otto L. T. Lam, Viraj K. Reddy, Yahya Al-Yousif, Florentin Racovitan & Nicole Askin. (2022) An overview of the characteristics and methodological standards across systematic reviews with Meta-analysis of efficacy/effectiveness of influenza antiviral drugs. Current Medical Research and Opinion 38:12, pages 2035-2046.
Read now
Read now
Sofía Tejada, Alexandre M. Tejo, Yolanda Peña-López, Carlos G. Forero, Xavier Corbella & Jordi Rello. (2021) Neuraminidase inhibitors and single dose baloxavir are effective and safe in uncomplicated influenza: a meta-analysis of randomized controlled trials. Expert Review of Clinical Pharmacology 14:7, pages 901-918.
Read now
Read now
Vanessa Taieb, Hidetoshi Ikeoka, Piotr Wojciechowski, Katarzyna Jablonska, Samuel Aballea, Mark Hill & Nobuo Hirotsu. (2021) Efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors in the treatment of influenza virus infection in high-risk and uncomplicated patients – a Bayesian network meta-analysis. Current Medical Research and Opinion 37:2, pages 225-244.
Read now
Read now
Naoki Hosogaya, Takahiro Takazono, Akira Yokomasu, Shinzo Hiroi, Hidetoshi Ikeoka, Kosuke Iwasaki, Tomomi Takeshima & Hiroshi Mukae. (2021) Estimation of the value of convenience in taking influenza antivirals in Japanese adult patients between baloxavir marboxil and neuraminidase inhibitors using a conjoint analysis. Journal of Medical Economics 24:1, pages 244-254.
Read now
Read now
Articles from other publishers (21)
Yunsong Li, Xiaoling Wang, Yufang Liao, Yanbin Zeng, Wanlong Lin & Wei Zhuang. (2024) Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system. BMC Infectious Diseases 24:1.
Crossref
Crossref
Hideyuki Ikematsu, Takamichi Baba, Masaya M. Saito, Masahiro Kinoshita, Shogo Miyazawa, Ayano Hata, Saki Nakano, Yoshitake Kitanishi & Frederick G. Hayden. (2024) Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial. Influenza and Other Respiratory Viruses 18:5.
Crossref
Crossref
Andrey G. Malyavin. (2023) Application of HS221GI in treatment of influenza and ARVI in adults: a new approach – managing virus-induced inflammation. Results of a double-blind, randomized, placebo-controlled, multicenter clinical trial. Terapevticheskii arkhiv 95:12, pages 1165-1171.
Crossref
Crossref
Katia DONADELLO, Leonardo GOTTIN, Riccardo PETTITI BOETTI & Ignacio MARTIN-LOECHES. (2023) Influenza management with new therapies. Minerva Respiratory Medicine 62:3.
Crossref
Crossref
Ken K.P. Chan & David S.C. Hui. (2023) Antiviral therapies for influenza. Current Opinion in Infectious Diseases 36:2, pages 124-131.
Crossref
Crossref
Jiaming Li, Keita Wagatsuma, Yuyang Sun, Isamu Sato, Takashi Kawashima, Tadashi Saito, Yasushi Shimada, Yasuhiko Ono, Fujio Kakuya, Nobuo Nagata, Michiyoshi Minato, Naoki Kodo, Eitaro Suzuki, Akito Kitano, Toshihiro Tanaka, Satoshi Aoki, Irina Chon, Wint Wint Phyu, Hisami Watanabe & Reiko Saito. (2023) Factors associated with viral RNA shedding and evaluation of potential viral infectivity at returning to school in influenza outpatients after treatment with baloxavir marboxil and neuraminidase inhibitors during 2013/2014–2019/2020 seasons in Japan: an observational study. BMC Infectious Diseases 23:1.
Crossref
Crossref
Natalia V. Breslav, Anna V. Ignatjeva, Evgeniya A. Mukasheva, Anastasiya S. Krepkaia & Elena I. Burtseva. (2023) Baloxavir marboxil as a new specific anti-influenza drug. Epidemiology and Infectious Diseases 27:4, pages 245-254.
Crossref
Crossref
Shogo Miyazawa, Takahiro Takazono, Naoki Hosogaya, Kazuko Yamamoto, Hideaki Watanabe, Masakazu Fujiwara, Satoki Fujita & Hiroshi Mukae. (2022) Comparison of Intra-Familial Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Oseltamivir Using an Influenza Transmission Model and a Health Insurance Claims Database. Clinical Infectious Diseases 75:6, pages 927-935.
Crossref
Crossref
Yonghong Zhao, Guangliang Huang, Wenjuan He, Qian Sun, Xiaojuan Zhao, Dan Li, Huichao Wang, Wenyan Cui & Xiuju Liu. (2022) Efficacy and safety of single‐dose antiviral drugs for influenza treatment: A systematic review and network meta‐analysis. Journal of Medical Virology 94:7, pages 3270-3302.
Crossref
Crossref
Hui-Chen Su, I-Jung Feng, Hung-Jen Tang, Mei-Fen Shih & Yi-Ming Hua. (2022) Comparative effectiveness of neuraminidase inhibitors in patients with influenza: A systematic review and network meta-analysis. Journal of Infection and Chemotherapy 28:2, pages 158-169.
Crossref
Crossref
Jakob J. Malin, Till Bunse, Christoph D. Spinner & Ulrike Protzer. (2022) Antivirale MedikamenteAntiviral drugs. Der Internist 63:1, pages 118-128.
Crossref
Crossref
Zhoupeng Li, Fang Wang, Yongsheng Liu, Dongshen Zhai, Xiaoxiao Zhang, Qikang Ying, Min Jia, Xiaoyan Xue, Jingru Meng, Jing Li, Xingan Wu & Mingkai Li. (2021) Coumarin Derivative N6 as a Novel anti-hantavirus Infection Agent Targeting AKT. Frontiers in Pharmacology 12.
Crossref
Crossref
Emanuele Palomba, Valeria Castelli, Giulia Renisi, Alessandra Bandera, Andrea Lombardi & Andrea Gori. (2021) Antiviral Treatments for Influenza. Seminars in Respiratory and Critical Care Medicine 42:06, pages 859-872.
Crossref
Crossref
Yu-Chi Kuo, Chih-Cheng Lai, Ya-Hui Wang, Chao-Hsien Chen & Cheng-Yi Wang. (2021) Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials. Journal of Microbiology, Immunology and Infection 54:5, pages 865-875.
Crossref
Crossref
Jen-Wei Liu, Shen-Hua Lin, Lin-Chien Wang, Hsiao-Yean Chiu & Jen-Ai Lee. (2021) Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children. JAMA Network Open 4:8, pages e2119151.
Crossref
Crossref
Sergey K. Zyryanov, Olga I. Butranova, Dmitry S. Gaidai & Kirill L. Kryshen. (2021) Pharmacotherapy for acute respiratory infections caused by influenza viruses: current possibilities. Terapevticheskii arkhiv 93:1, pages 114-124.
Crossref
Crossref
Jiro Fujita. (2020) Clinical application of baloxavir marboxil in the treatment of influenza. Respiratory Investigation 58:5, pages 301-304.
Crossref
Crossref
Matt Shirley. (2020) Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza. Drugs 80:11, pages 1109-1118.
Crossref
Crossref
Leo Yi Yang Lee, Jie Zhou, Rebecca Frise, Daniel H. Goldhill, Paulina Koszalka, Edin J. Mifsud, Kaoru Baba, Takahiro Noda, Yoshinori Ando, Kenji Sato, Aoe-Ishikawa Yuki, Takao Shishido, Takeki Uehara, Steffen Wildum, Elke Zwanziger, Neil Collinson, Klaus Kuhlbusch, Barry Clinch, Aeron C. Hurt & Wendy S. Barclay. (2020) Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission. PLOS Pathogens 16:4, pages e1008395.
Crossref
Crossref
Xuyun Peng, Yichun Xiao, Li Li, Dongxiang Wen, Xiaoyan Gong, Bingfei Li & Lili Zhou. (2020) Curative efficacy and safety of peramivir in the treatment of children suspected with influenza. European Journal of Inflammation 18, pages 205873922094613.
Crossref
Crossref
Eris Cani, Tae Eun Park & Rebecca Kavanagh. 2019. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
301
319
.